CONTEXT: @entity3645 and @entity30361 ( @entity30361 ) have been suggested as key mediators of the improvements in @entity413 metabolism after Roux-en-Y gastric bypass (RYGB). OBJECTIVE: To describe fasting and postprandial state total @entity6741 (TBA) and @entity30361 concentrations before and after RYGB and relate them to parameters of @entity413 metabolism, @entity6757 , @entity13216 and @entity165 fractions. DESIGN _ SETTING: Prospective descriptive study, performed at the Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark. @entity1 : 13 @entity2175 ( @entity2175 ) @entity1 and 12 normal @entity413 tolerant (NGT) subjects. INTERVENTION: Four-hour liquid meal test performed before, 1 week, 3 months and 1 year after RYGB. MAIN OUTCOME MEASURES: Fasting and postprandial TBA and @entity30361 concentrations. RESULTS: Fasting TBA concentrations decreased in NGT subjects (p<0.001) and were unchanged in @entity2175 @entity1 one week after surgery, but then increased gradually in both groups with time from surgery (ANOVA ptime<0.001). AUC TBA was decreased in NGT subjects 1 week after RYGB (pre: 567 mmol x min/L [481-826], 1wk: 419 [381-508], p=0.009) and unchanged in @entity2175 @entity1 (894 [573-1002], 695 [349-1147]; p=0.97) but then increased with time from surgery in both groups (ptime<0.001). Fasting @entity30361 concentrations were unchanged acutely after RYGB (NGT: 140 pg/mL [100-162]; 134 [119-204], p=0.42; @entity2175 : 162 [130-196], 154 [104-164], p=0.68) and remained unchanged throughout the follow-up period. AUC @entity30361 increased gradually with time after surgery (ptime<0.001), resembling the changes seen with AUC TBA. One week after RYGB, @entity413 metabolism improved, LDL- and HDL- @entity165 decreased, @entity13216 and @entity6757 secretion increased, whilst FFA concentrations were unchanged. CONCLUSION: TBA and @entity30361 do not explain acute changes in @entity413 metabolism, @entity165 fractions and gut hormone secretion after RYGB.

IMPROVEMENTSIN XXXX METABOLISM EARLY AFTER GASTRIC BYPASS SURGERYARE NOT EXPLAINED BY INCREASES IN TOTAL BILE ACIDS AND FIBROBLASTGROWTH FACTOR 19 CONCENTRATIONS.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity2175 :: ('MESH:D003924', 'Disease') :: ['type 2 diabetic', 'T2D'] @entity30361 :: ('9965', 'Gene') :: ['fibroblast growth factor 19', 'FGF19'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['Cholesterol', 'cholesterol'] @entity6741 :: ('CHEBI:3098', 'Chemical') :: ['bile acid'] @entity6757 :: ('100125288', 'Gene') :: ['GLP-1'] @entity3645 :: ('MESH:D001647', 'Chemical') :: ['Bile acids'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity13216 :: ('885', 'Gene') :: ['CCK']
@entity413 :: (MESH:D005947,Chemical) :: ['GLUCOSE']
